一项随机,开放标签,多中心,并行控制研究的协议,评估修改后的双过血化疗法,用于治疗败血栓冲击
Lei Zhang1, Guan Wang1, Yanrui Chen2
1Department of Critical Care, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Blood purification
|August 15, 2025
概括
修改的双过等离子体化 (M-DFPP) 可能会改善败血症休克患者的生存率. 这项试验调查了M-DFPPPP.
科学领域:
- 关键护理医学 关键护理医学
- 免疫学 免疫学 免疫学
- 脏替代疗法治疗 脏替代疗法
背景情况:
- 败血性休克 (SS) 涉及持续的低血压,尽管液体复苏.
- 经过修改的双过等离子酶 (M-DFPP) 消除炎症介质,同时保留蛋白质.
- M-DFPP旨在恢复免疫平衡并稳定SS中的血液动力学.
研究的目的:
- 评估M-DFPP在改善败血症休克患者的生存率方面的疗效.
- 评估M-DFPP对减少炎症介质的影响.
- 为了确定血管活性药物需求和器官功能障碍的变化.
主要方法:
- 随机对照试验招募符合条件的SS患者.
- 纳入标准:早期完成以目标为导向的治疗和使用北上腺素.
- 干预组接受M-DFPP;主要终点是28天全因死亡率.
主要成果:
- 主要终点:28天全因死亡率.
- 二级终点:减少炎症媒介,血管活性药物需求和器官功能障碍.
- 数据分析将侧重于将M-DFPP治疗与标准护理进行比较.
结论:
- M-DFPP在治疗败血症休克方面表现有前途.
- 需要进一步的大规模试验来优化M-DFPP协议.
- 最佳的患者选择,时间和频率需要澄清.
更多相关视频
相关概念视频
Continuous Renal Replacement Therapy
143
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
143
Acute Kidney Injury V: Interprofessional Care
44
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
44


